Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious bleeding and thrombotic disorders, announced that it has completed a $157 million Series C financing. The oversubscribed funding round was led by Sofinnova Partners, with participation from a large long-only global asset management firm, a major global sovereign wealth fund, and Avoro Capital Advisors, alongside existing investors RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital.
The new funding will prepare Hemab for registration studies following the successful Phase 2 advancement of sutacimig in Glanzmann thrombasthenia (GT) and continued progress of HMB-002 in Von Willebrand Disease (VWD). The company also plans to expand its clinical pipeline with additional drug candidates, reinforcing its long-term goal of building what it calls “the ultimate clotting company.”
Sutacimig is being developed as the first-ever prophylactic therapy for Glanzmann thrombasthenia, a rare and potentially life-threatening bleeding disorder. Following promising Phase 2 results, Hemab plans to initiate a registration study in 2026 and expand into a Phase 2 study in Factor VII deficiency.
The company is also advancing HMB-002, an antibody-based treatment targeting the underlying pathophysiology of Von Willebrand Disease. Phase 1 data show that HMB-002 increases both Von Willebrand Factor and Factor VIII levels, offering a novel approach to addressing the root cause of VWD rather than managing symptoms.
Hemab’s development programs are informed by its GT360, FVIID360, and VWD360 natural history studies, which have provided deep insights into patient experiences, revealing the physical and emotional burden of chronic bleeding disorders that have historically lacked effective prophylactic therapies.
How the funding will be used: With the Series C funding, Hemab intends to advance additional programs into clinical development, including HMB-003, expected to be announced in the first half of 2026. The company’s expanding pipeline reflects its mission to provide innovative, durable treatment options for patients facing significant unmet medical needs in rare bleeding disorders.
KEY QUOTES
“As a mother of two boys with GT, I live with a constant fear, knowing from experience that a simple fall or injury can lead to a life-threatening bleed. We feel so limited by the lack of effective treatments in the event of an emergency and cannot stress enough how urgently we feel the need for breakthrough treatments. Our greatest hope is to offer our children a treatment that will allow them to live normal lives. Investment in the development of modern therapies for these underserved patients brings hope to our family.”
Alexandra Sullivan, Patient Advocate and Mother
“For too long, people living with von Willebrand Disease have watched from the sidelines as breakthrough prophylactic therapies transformed hemophilia care. HMB-002 represents hope: in its potential to be the kind of innovative, patient-centered treatment our community has been waiting for. It’s time VWD patients had access to the same caliber of medicine that has already changed lives in hemophilia.”
Jeanette Cesta, Executive Director, VWD Connect Foundation
“The quality of our investor syndicate and this significant financing validate our approach and enable us to continue building what we believe will become the ultimate clotting company. We carefully listen to people living with clotting diseases and collaborate closely with patients and families affected by these conditions and families to deliver 21st century treatment options. Hemab’s unprecedented deep domain expertise in clotting science, combined with our team’s proven capabilities in advancing programs from early development through approval and commercialization, uniquely positions us to deliver breakthrough therapies. This funding accelerates our mission of transforming lives for people who have waited far too long.”
Benny Sorensen, MD, PhD, Chief Executive Officer, Hemab Therapeutics
“Hemab’s focus on patients and an innovative approach to treating neglected bleeding disorders, combined with their deep scientific excellence and strong clinical execution, makes it a standout company in the biotech landscape. Hemab’s progress across multiple clinical programs gives us confidence in the team’s ability to execute on their ambitious pipeline. We’re excited to support their mission to bring transformative treatments to underserved patient populations with significant medical needs.”
Joe Anderson, PhD, Partner, Sofinnova Partners
